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19th CardioVascular Summit: TCTAP 2014between the BES and ZES, including MACE (5.5 vs. 6.4%; p ¼0.76) and stent
thrombosis (0.3 vs. 0.3%; p ¼ 0.99). The secondary endpoints also were not signif-
icantly different between BES and ZES, including target lesion failure (2.0 vs. 1.6%; p
¼ 0.53), in-segment LL (mm) at 12 months (0.090.37 vs. 0.050.39, p ¼0.61).
OCT at 6 month revealed that mean NIH thickness (mm) of BES and ZES were
59.130.3, 54.025.6, respectively (p¼0.49), and uncovered stent strut percentage
(%) of BES and ZES were 20.521.8, 17.722.4, respectively (p¼0.63).
Conclusion: BES with biodegradable polymer with 6 month DAPT did not increase
the risk of MACE, stent thrombosis, target lesion failure, and LL at 12 months
comparing with ZES with durable polymer. The 2nd generation DES including BES
and ZES are comparably efﬁcacious. Our results need to be conﬁrmed in larger trials,
and further follow up data.
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Background: Coronary artery disease in Asian populations is rising and is
commonly treated with drug-eluting stents (DES). Clinical evidence is needed on
outcomes of new-generation DES implantation in Asian patients with lesions in more
than 1 vessel.
Methods: Patients with de novo lesions (length 27 mm and reference vessel
diameter 2.25-4.0 mm) in 2 vessels were enrolled from 24 sites across Asia. The
Resolute(R) zotarolimus-eluting stent (R-ZES) was implanted in both lesions at the
same index procedure. Postprocedure dual antiplatelet therapy (DAPT) was recom-
mended for 6 to 12 months. An independent clinical events committee adjudicated all
events. The primary endpoint was 1-year target vessel failure (TVF; cardiac death,
target vessel myocardial infarction [TVMI], or clinically-driven target vessel revas-
cularization [TVR]). A secondary endpoint was target lesion failure (TLF; cardiac
death, TVMI, or clinically-driven target lesion revascularization [TLR]).
Results: There were 202 subjects (n¼406 lesions) enrolled. The mean age was 60.1
years (standard deviation [SD], 9.8), 85% (n¼171) of patients were male, and 46%
(n¼93) had diabetes. DAPT use was 92% (n¼185/201) at 6 months and 91% (n¼182/
201) at 1 year. Mean lesion length was 15.3 mm (SD, 6.6) and 61.1% were ACC/AHA
class B2/C. The rate of TVF at 1 year was 4.5% (n¼9/202); the rate of TLF was 4.0%
(n¼8/202). Cardiac death occurred in 0.5% (n¼1) of patients, TVMI in 2.5% (n¼5),
clinically-driven TVR in 1.5% (n¼3), and clinically-driven TLR in 1.5% (n¼3). There
were no events of Academic Research Consortium deﬁnite or probable stent
thrombosis.
Conclusion: Use of the R-ZES was safe and effective with a low rate of clinical
events and no stent thrombosis events in Asian patients with dual-vessel coronary
artery disease.
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Background: The efﬁcacy of drug eluting stent for saphenous vein graft (SVG) is
proven, however the difference of the location of the recipient artery remains unclear.
In this study, we compared angiographic outcome for SVG, including in-stent reste-
nosis (ISR), stent fracture (SF) or target lesion revascularization (TLR) among
recipient native vessel territory (left circumﬂex artery group versus left ascending and
right coronary artery group).
Methods: From February 2004 to January 2013, 45 patients with 68 lesions under-
went drug-eluting stent implantation in SVG. Angiographic follow-up at 3-6 months
was obtained in 45 lesions (follow-up rate; 66%).
Results: Data are shown in the table.
Conclusion: Recurrence of ISR is frequent in the LCX group after DES implantation
for SVG lesions. The location of recipient artery should be taken into account in case
of treatment of SVG lesions after DES implantation.JACC Vol 63/12/Suppl S j April 22–25, 2014 j TCTAP Abstracts/ORATCTAP A-073
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Background: In spite of availability of drug-eluting stent (DES), clinical outcome of
percutaneous coronary intervention for right coronary ostial lesion (RCAos) is still
poor. So we investigated the angiographic and clinical outcome of DES implantation
for True RCAos.
Methods: This was a single center non-randomized retrospective study. From April
2007 to July 2012, 67 consecutive patients who underwent DES implantation for
de novo RCAos were included. RCAos was deﬁned as the lesion being within
3 mm of the ostium. We deﬁned True RCAos as lesion contained just RCA ostium.
Subjects were classiﬁed into two groups: the patients treated for True RCAos (True
group, 35 patients) and for Not true RCAos (Not true group, 32 patients). Endpoint
was binary restenosis at 10 months and target lesion revascularization (TLR) at
12 months.
Results: True group was older than Not true group. There were no signiﬁcant dif-
ferences between two groups in gender, hypertension, hyperlipidemia, diabetes, and
hemodialysis. Despite True group had shorter stent length and larger lesion diameter,
they had a higher rate of binary restenosis at 10 months (35.5% vs. 10.0%, p<0.05)
and TLR at 12 months (28.6% vs. 6.3%, p<0.05) than Not true group.
Conclusion: Our data indicates that the outcome of DES implantation for True
RCAos is worse than that of DES implantation for Not true RCAos.
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Background: The purpose of this study was to evaluate clinical outcomes of drug-
eluting stent (DES) according to on versus off-label indication for 5 years.
Methods: A total of 929 consecutive patients who performed percutaneous coronary
intervention (PCI) with DES from April 2005 to December 2007 were enrolled. Those
patients were divided into two groups according to on (n¼449) versus off-label
(n¼480) indication. Off label usage of DES was indicated in patients with long ste-
notic lesion (>30mm), total occlusion, bifurcation, ostial lesion, left main disease,
multivessel disease, saphenous vein graft and thrombus present. Clinical outcomes of
major adverse cardiac event (MACE) including death, target vessel revascularization
(TVR), target lesion revascularization (TLR), myocardial infarction (MI) and stent
thrombosis (ST) were compared between two groups for 5 years. Risk factors for
MACE according to on versus off label indication.
Results: There were no difference between two groups in baseline characteristics,
except diabetes (24.9% [Group 1] vs. 35.4%[Group 2], p¼0.002). Of 929 patients
enrolled in this study, seven hundred ten patients were completely monitored for
5years (follow up rate 76.4%). At one year, group 2 was associated of higher inci-
dence of MACE (1.9% vs. 7.5%, p¼0.000), because of TLR(1.4% vs. 3.4%,
p¼0.047), TVR(1.6% vs. 5.2%, p¼0.004) and stent thrombosis(0.2% vs. 1.5%,
p¼0.042). From 1 year until 5 year clinical follow up, group 2 also had a higher
incidence of MACE(6.4% vs. 11.3%, p¼0.014) because of TLR(3.7% vs. 7.1%,
p¼0.029). The rate of total MACE were higher in off-label usage than those of
on-label (9.1% vs. 20.0%, p¼0.000). Multivessel disease [HR 2.0, p¼0.004] and
diabetes [HR 1.7 p¼0.017] were independent risk factors for MACE in multivariate
analysis.
Conclusion: Patients with On-label indication of DES had better long-term clinical
outcomes than those with off-label. Further large clinical trials will be warranted.L/Drug-eluting Stents S21
